Halidjan Kamilov, Munirahon Kasimova, Dilbar Makhkamova


The purpose of this study was to investigate the content neurospecific markers protein S-100 and neuroenolaza in blood serum and tear fluid of patients with ocular ischemic syndrome.

Material and methods. We observed 43 patients aged 57 to 79 years, mean age 67.3 ± 2.7 years. Control group consisted of 11 volunteers  without ophthalmic symptoms. The main group consisted of 32 patients with OIS. The neurospecific proteins S100 and NSE were investigated in blood serum and tear fluid.

Results. The study found that in patients of the control group the content of protein were within the normal range: S- 100 in the tear fluid – 0,0662 ± 0,00335 mkg/l, in the blood serum 0,0508 ± 0,00241 mkg/l. In patients of the main group the indicators of protein in the tear fluid were elevated in all patients - 3,12 ± 0,246 mkg/l ( p<0.005). The normal levels in blood serum of marker S-100 was in 30 patients - 0,0589 ± 0,00303 mkg/l, while, in 2 patients protein S-100 were raised and averaged 0,2175±0,00725 mkg/l. It was found that in patients of the control group content of protein NSE in the tear fluid and blood serum were within normal values - 15,86 ± 0,148 Ng/ml, 15,60 ± 0,202 Ng/ml respectively. In the main group the amount of protein NSE tended to increase in the tear fluid in 23 patients and averaged 33,012 ± 3,2626 Ng/ml (p<0.005), a significant decrease the quantity of protein was observed in 9 patients, which amounted to 5,166 ± 0,8301 Ng/ml. At normal levels in the blood serum protein NSE detected in 30 patients and averaged 14,48 ± 0,263 Ng/ml, whereas, in 2 patients there was a significant increase of content of protein NSE and was 27,47 ± 3,068 Ng/ml.

Conclusions. Thus, changes in the concentration of S100 and neuroenolaza in the tear fluid in patients with ocular ischemic syndrome allow to identify as marker of nerve cells damage of the eye, contributing to the definition in conjunction with other signs of stage and etiology of the disease.


ocular ischemic syndrome, ocular ischemic diseases, protein S-100, neuroenolaza, neurospecific markers.

Full Text:



Alfred, N., Fonteh, R., & Biringer, T. (2006). Nervous system. Markers disorders of the nervous system.

Blinov, D. (2004). Immunosorbent assay neurospecific antigens in evaluating BBB permeability with hypoxic-ischemic lesions of the central nervous system. MD Dissertation in Medicine. Moscow.

Chehonin. V., Lebedev. S., & Petrov. S. (2004). Modeling of focal cerebral ischemia. Bulletin of Medical Sciences, 3, 1-56.

Dzhengurova, A. (2007). Infrared spectrometry of tear fluid in the diagnosis of acute circulatory disorders of retinal vessels and optic nerve. MD Dissertation in Medicine. Moscow.

Grigoriev, E., (2010). Neuronspecific proteins - markers encephalopathy in severe concomitant injury. Medical emergency conditions, 2, 27.

Jacques, B. (2013). Pathophysiology of the cerebral circulation during cardiac surgery. Meeting abstracts. Neurological complications after cardiac surgery, 4. B. Germany.

Kamenskikh, T., Zaharova, N., Kolbenev, I., Kamenskikh, I., & Sidelnikova, V. (2013). Investigation of the molecular mechanisms of regulation of apoptosis of retinal ganglion cells in glaucoma. Clinical Ophthalmology, 2, 46-49.

Makkaeva, S. (2009). Features of ocular ischemic syndrome with vascular encephalopathy. PhD Dissertation in Medicine. Moscow.

Martynova, G., Skvortsov, V., Petrov, S., & Chekhonin, V., (2007). Biomarkers of inflammatory central nervous system disorders. Annals of clinical and experimental neurology, 2, 67-69.

Petrov, S., Lebedev. S., Turina. O., Chehonin. V., (2005). Immunochemical verification chronic neurodegenerative process in rats after middle cerebral artery occlusion. Journal of Neurochemistry, 2, 133-137.

Shakeri, M. Mahdkhah, A., & Panahi, F. (2013). S100B protein as a post-traumatic biomarker for prediction of brain death in association with patient outcomes. Archives of Trauma Research, 2(2), 76-80.

Routsi, Ch., (2009). Increased levels of serum s100b protein in critically-ill patients without brain injury. Shock, 1, 20-24.

DOI: http://dx.doi.org/10.12955/emhpj.v7i2.522


  • There are currently no refbacks.

Print ISSN 1804-5804, Online ISSN 1804-9702

(c) 2018 CBU,o.p.s.